Clear All
11110 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83718-0000-01 83718-0000 Toripalimab-tpzi LOQTORZI 240.0 mg/6mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Oct 27, 2023 In Use
83703-0562-01 83703-0562 PEMETREXED PEMETREXED 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog INTRAVENTRICULAR Aug 18, 2022 In Use
83703-0561-01 83703-0561 PEMETREXED PEMETREXED 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Aug 18, 2022 In Use
83703-0533-01 83703-0533 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec 15, 2022 In Use
83703-0532-01 83703-0532 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
83703-0531-02 83703-0531 Palonosetron hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov 12, 2021 In Use
83634-0779-02 83634-0779 Metoclopramide hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jun 30, 2024 In Use
83634-0777-05 83634-0777 Palonosetron hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 15, 2024 In Use
83634-0776-10 83634-0776 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb 28, 2024 In Use
83634-0203-74 83634-0203 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Feb 28, 2024 In Use
83634-0202-61 83634-0202 Melphalan hydrochloride Melphalan Hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec 18, 2023 In Use
83513-0010-01 83513-0010 Docetaxel BEIZRAY 20.0 mg/ml Chemotherapy Antimitotic Agent Taxane Intravenous Oct 23, 2024 In Use
83257-0005-41 83257-0005 Pegfilgrastim-jmdb Fulphila 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Oct 1, 2023 In Use
83257-0004-12 83257-0004 Trastuzumab-dkst OGIVRI Immunotherapy Monoclonal Antibody HER2 Oct 1, 2023 In Use
83257-0003-01 83257-0003 Trastuzumab-dkst OGIVRI 420.0 mg/20mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 1, 2023 In Use
83257-0001-11 83257-0001 Trastuzumab-dkst OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Oct 1, 2023 In Use
83090-0010-10 83090-0010 Arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov 9, 2023 In Use
83090-0010-01 83090-0010 Arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov 9, 2023 In Use
83090-0009-10 83090-0009 Arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov 9, 2023 In Use
83090-0009-01 83090-0009 Arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov 9, 2023 In Use
83090-0008-01 83090-0008 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Jul 15, 2023 In Use
83008-0074-20 83008-0074 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 25, 2024 In Use
83008-0074-30 83008-0074 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 25, 2024 In Use
83008-0061-21 83008-0061 METHYLPREDNISOLONE METHYLPREDNISOLONE 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 21, 2024 In Use
83008-0026-65 83008-0026 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct 3, 2023 In Use

Found 11110 results — Export these results